In today's edition of Market Checkup, health-care analysts David Williamson and Max Macaluso take a close look at Onyx Pharmaceuticals, which may or may not be acquired in the coming weeks, and Eli Lilly, which recently announced positive clinical trial results for an experimental cancer drug.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
The Motley Fool's health-care show, "Market Checkup," for August 15, 2013.
David Williamson owns shares of Pfizer. Max Macaluso, Ph.D. owns shares of Celgene. The Motley Fool recommends Celgene. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Related Articles
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
Hims & Hers Stock Investors Need to Know This Before Buying or Selling This Growth Stock
Hims & Hers Stock Financial Analysis Following Huge Stock Price Crash
Which Stock Will Dominate the Weight Management Market Through 2030?
3 No-Brainer Stocks to Buy for Under $100 Right Now
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.